This company has been marked as potentially delisted and may not be actively trading. Anchiano Therapeutics (ANCN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock ANCN vs. MRNS, HILS, ALLK, CARA, NNVC, IBIO, ME, GLYC, AEON, and OBSVShould you be buying Anchiano Therapeutics stock or one of its competitors? The main competitors of Anchiano Therapeutics include Marinus Pharmaceuticals (MRNS), Hillstream BioPharma (HILS), Allakos (ALLK), Cara Therapeutics (CARA), NanoViricides (NNVC), iBio (IBIO), 23andMe (ME), GlycoMimetics (GLYC), AEON Biopharma (AEON), and ObsEva (OBSV). These companies are all part of the "medical" sector. Anchiano Therapeutics vs. Its Competitors Marinus Pharmaceuticals Hillstream BioPharma Allakos Cara Therapeutics NanoViricides iBio 23andMe GlycoMimetics AEON Biopharma ObsEva Anchiano Therapeutics (NASDAQ:ANCN) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment. Do analysts rate ANCN or MRNS? Marinus Pharmaceuticals has a consensus price target of $3.92, indicating a potential upside of 613.29%. Given Marinus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Marinus Pharmaceuticals is more favorable than Anchiano Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anchiano Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Marinus Pharmaceuticals 0 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.40 Is ANCN or MRNS more profitable? Anchiano Therapeutics has a net margin of 0.00% compared to Marinus Pharmaceuticals' net margin of -446.48%. Anchiano Therapeutics' return on equity of 36.08% beat Marinus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Anchiano TherapeuticsN/A 36.08% 27.40% Marinus Pharmaceuticals -446.48%-7,831.35%-120.74% Which has preferable earnings & valuation, ANCN or MRNS? Anchiano Therapeutics has higher earnings, but lower revenue than Marinus Pharmaceuticals. Anchiano Therapeutics is trading at a lower price-to-earnings ratio than Marinus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnchiano TherapeuticsN/AN/A-$27.12M-$3.46-0.33Marinus Pharmaceuticals$30.99M0.98-$141.40M-$2.47-0.22 Which has more risk & volatility, ANCN or MRNS? Anchiano Therapeutics has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Does the media refer more to ANCN or MRNS? In the previous week, Anchiano Therapeutics' average media sentiment score of 0.00 equaled Marinus Pharmaceuticals'average media sentiment score. Company Overall Sentiment Anchiano Therapeutics Neutral Marinus Pharmaceuticals Neutral Do institutionals & insiders believe in ANCN or MRNS? 9.1% of Anchiano Therapeutics shares are owned by institutional investors. Comparatively, 98.8% of Marinus Pharmaceuticals shares are owned by institutional investors. 6.9% of Anchiano Therapeutics shares are owned by company insiders. Comparatively, 5.5% of Marinus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryMarinus Pharmaceuticals beats Anchiano Therapeutics on 8 of the 14 factors compared between the two stocks. Get Anchiano Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANCN vs. The Competition Export to ExcelMetricAnchiano TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.58M$828.42M$5.53B$9.09BDividend YieldN/A4.84%5.06%4.01%P/E Ratio7.711.3728.2220.40Price / SalesN/A237.56374.4580.80Price / CashN/A17.6924.7227.46Price / Book0.586.488.255.56Net Income-$27.12M-$23.77M$3.19B$251.39M Anchiano Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANCNAnchiano TherapeuticsN/A$1.16-0.3%N/A+4.3%$8.58MN/A7.7116Gap UpMRNSMarinus Pharmaceuticals2.069 of 5 stars$0.55-0.2%$3.92+613.3%-59.9%$30.32M$30.99M-0.22110HILSHillstream BioPharmaN/A$1.69-9.1%N/A-54.9%$29.75MN/A-2.351ALLKAllakos3.3615 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190CARACara Therapeutics0.2208 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumeNNVCNanoViricides0.3125 of 5 stars$1.39+0.7%N/A-19.8%$22.34MN/A-1.9320News CoveragePositive NewsIBIOiBio1.2984 of 5 stars$0.84+6.5%$4.30+414.5%-66.6%$13.81M$375K0.00100ME23andMeN/A$0.50-35.3%N/A-94.8%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeGLYCGlycoMimetics1.0017 of 5 stars$0.16-6.6%N/A-99.5%$10.00M$10K-0.3450High Trading VolumeAEONAEON Biopharma2.4266 of 5 stars$0.84+6.1%$360.00+42,741.8%-99.2%$9.50MN/A4.675Gap UpOBSVObsEvaN/AN/AN/AN/A$7.94MN/A-0.1150Gap Up Related Companies and Tools Related Companies MRNS Alternatives HILS Alternatives ALLK Alternatives CARA Alternatives NNVC Alternatives IBIO Alternatives ME Alternatives GLYC Alternatives AEON Alternatives OBSV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANCN) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anchiano Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anchiano Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
